Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease
暂无分享,去创建一个
Michael J. Devine | C. Dobson | D. Klenerman | N. Wood | M. Horrocks | S. Gandhi | P. Gissen | A. Abramov | P. Angelova | N. Cremades | Serene W. Chen | M. H. Ludtmann | Daniel Little | M. Devine | Plamena R. Angelova | B. Banushi | E. Deas | Z. Yao
[1] H. Schmidt,et al. Evolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target Engagement. , 2015, Antioxidants & redox signaling.
[2] D. Klenerman,et al. Aggregated α-synuclein and complex I deficiency: exploration of their relationship in differentiated neurons , 2015, Cell Death and Disease.
[3] C. Dobson,et al. Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation , 2015, Proceedings of the National Academy of Sciences.
[4] D. Klenerman,et al. Lipid peroxidation is essential for α‐synuclein‐induced cell death , 2015, Journal of neurochemistry.
[5] M. Walker,et al. Seizure activity results in calcium- and mitochondria-independent ROS production via NADPH and xanthine oxidase activation , 2014, Cell Death and Disease.
[6] DuhamelAlain,et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. , 2014 .
[7] N. Wood,et al. PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice , 2014, Open Biology.
[8] S. Kovac,et al. Lipid peroxidation is essential for phospholipase C activity and the inositol-trisphosphate-related Ca2+ signal , 2014, Journal of Cell Science.
[9] David R. Brown. α-Synuclein as a ferrireductase. , 2013, Biochemical Society transactions.
[10] D. Surmeier,et al. Calcium Entry and α-Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons , 2013, The Journal of Neuroscience.
[11] O. Hwang. Role of Oxidative Stress in Parkinson's Disease , 2013, Experimental neurobiology.
[12] S. Lukyanov,et al. HyPer-3: a genetically encoded H(2)O(2) probe with improved performance for ratiometric and fluorescence lifetime imaging. , 2013, ACS chemical biology.
[13] Christopher M. Dobson,et al. Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.
[14] S. Gandhi,et al. Mechanism of Oxidative Stress in Neurodegeneration , 2012, Oxidative medicine and cellular longevity.
[15] Blaine R. Roberts,et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease , 2012, The Journal of experimental medicine.
[16] Patrick A. Lewis,et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus , 2011, Nature communications.
[17] M. Verbeek,et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2011, Neurology.
[18] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[19] F. Marken,et al. The synucleins are a family of redox-active copper binding proteins. , 2011, Biochemistry.
[20] David R. Brown,et al. Opus: University of Bath Online Publication Store Alpha-synuclein Is a Cellular Ferrireductase , 2022 .
[21] J. Andersen,et al. Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo , 2010, Neuroscience Letters.
[22] T. Tokuda,et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.
[23] S. Gandhi,et al. Dopamine Induces Ca2+ Signaling in Astrocytes through Reactive Oxygen Species Generated by Monoamine Oxidase , 2010, The Journal of Biological Chemistry.
[24] V. Uversky,et al. Metalloproteomics and metal toxicology of α-synuclein. , 2010, Metallomics : integrated biometal science.
[25] J. Imlay,et al. The iron-sulfur clusters of dehydratases are primary intracellular targets of copper toxicity , 2009, Proceedings of the National Academy of Sciences.
[26] N. Avadhani,et al. Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.
[27] J. Andersen,et al. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age , 2007, Neurobiology of Aging.
[28] R. Tanzi,et al. The 5′-untranslated region of Parkinson's disease α-synuclein messengerRNA contains a predicted iron responsive element , 2007, Molecular Psychiatry.
[29] D. Sulzer,et al. α-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration , 2006, The Journal of Neuroscience.
[30] C. Griesinger,et al. Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. , 2006, Journal of the American Chemical Society.
[31] C. Dobson,et al. Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.
[32] M. Duchen,et al. Expression and Modulation of an NADPH Oxidase in Mammalian Astrocytes , 2005, The Journal of Neuroscience.
[33] R. Hayward. Stress , 2005, The Lancet.
[34] B. Halliwell,et al. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? , 2004, British journal of pharmacology.
[35] M. Duchen,et al. β-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase , 2004, The Journal of Neuroscience.
[36] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[37] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[38] David R. Brown,et al. Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106–126 , 2003, Neuroscience Letters.
[39] A. Bush. Metal complexing agents as therapies for Alzheimer’s disease , 2002, Neurobiology of Aging.
[40] Robert Burke,et al. Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[41] P. Lansbury,et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. , 2002, Journal of molecular biology.
[42] V. Subramaniam,et al. Dependence of α-synuclein aggregate morphology on solution conditions , 2002 .
[43] C. Dobson,et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases , 2002, Nature.
[44] P. Lansbury,et al. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.
[45] E. Junn,et al. Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.
[46] M. Duchen,et al. Quantitative imaging of glutathione in hippocampal neurons and glia in culture using monochlorobimane , 2001, Journal of neuroscience research.
[47] D. Allsop,et al. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. , 2001, Current topics in medicinal chemistry.
[48] H. Niznik,et al. Direct binding and functional coupling of α‐synuclein to the dopamine transporters accelerate dopamine‐induced apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[49] H. Niznik,et al. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[50] Sarah J. Tabrizi,et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .
[51] T. Montine,et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.
[52] A J Lees,et al. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. , 1993, Brain : a journal of neurology.
[53] C. Marsden,et al. Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.
[54] C. Marsden,et al. INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN , 1987, The Lancet.
[55] Voon Wee Yong,et al. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.
[56] N. Wood,et al. PINK1 deficiency in b-cells increases basal insulin secretion and improves glucose tolerance in mice. , 2014, Open biology.
[57] L. Defebvre,et al. Targeting Chelatable Iron as a Therapeutic Modality in Parkinson ’ s Disease , 2016 .
[58] I. Ferrer,et al. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. , 2006, Neurobiology of aging.
[59] A. Singleton,et al. alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.
[60] V. Subramaniam,et al. Dependence of alpha-synuclein aggregate morphology on solution conditions. , 2002, Journal of molecular biology.
[61] S. Tabrizi,et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. , 2000, Human molecular genetics.
[62] G. Perry,et al. Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.